Journal article
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2)
- Abstract:
-
Background: To address the unmet medical need for an effective prophylactic vaccine against Ebola virus we assessed the safety and immunogenicity of three different two-dose heterologous vaccination regimens with a replication-deficient adenovirus type 26 vector-based vaccine (Ad26.ZEBOV), expressing Zaire Ebola virus glycoprotein, and a non-replicating, recombinant, modified vaccinia Ankara (MVA) vector-based vaccine, encoding glycoproteins from Zaire Ebola virus, Sudan v...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 261.4KB, Terms of use)
-
- Publisher copy:
- 10.1016/S1473-3099(20)30476-X
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Infectious Diseases More from this journal
- Volume:
- 21
- Issue:
- 4
- Pages:
- 493-506
- Publication date:
- 2020-11-17
- Acceptance date:
- 2020-05-06
- DOI:
- EISSN:
-
1474-4457
- ISSN:
-
1473-3099
- Language:
-
English
- Keywords:
- Pubs id:
-
1137412
- Local pid:
-
pubs:1137412
- Deposit date:
-
2020-10-13
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2020
- Rights statement:
- © 2020 Elsevier Ltd. All rights reserved.
- Notes:
- This is the accepted manuscript version of the article. The final version is available from Elsevier at: https://doi.org/10.1016/S1473-3099(20)30476-X
If you are the owner of this record, you can report an update to it here: Report update to this record